The impact of utilizing hepatitis c virus nucleic acid test-positive donor hearts on heart transplant waitlist time and transplant rate
Previous studies suggest that direct-acting antivirals (DAAs) for treatment of hepatitis C virus (HCV) infection permits transplantation of HCV-viremic donor organs in uninfected recipients. This opportunity may expand donor pool. We assessed the impact of utilizing HCV nucleic acid test-positive (NAT+) donor hearts on heart transplant (HTx) waitlist time and transplant rate.
Source: The Journal of Heart and Lung Transplantation - Category: Transplant Surgery Authors: Yan K. Gernhofer, Michela Brambatti, Barry H. Greenberg, Eric Adler, Saima Aslam, Victor Pretorius Tags: Original Clinical Science Source Type: research
More News: Cardiology | Heart | Heart Transplant | Hepatitis | Hepatitis C | Lung Transplant | Science | Study | Transplant Surgery | Transplants